Topical immunotherapy with diphencyprone (DPCP) for the treatment of severe alopecia areata has been used since 1983 and is felt to be the treatment of choice by many dermatologists. Although there have been no major side effects reported since its initial use, there remain some unknowns regarding its safety. Because DPCP has at least a 40% success rate for cosmetically acceptable regrowth in e...

Background: Topical immunotherapy with diphencyprone (DPCP) for the treatment of severe alopecia areata has been used since 1983 and is felt to be the treatment of choice for chronic extensive alopecia areata. Highly variable results have been reported. The purposes of this study were to evaluate the efficacy of DPCP in the treatment of chronic, extensive alopecia areata and to assess the...

Background: Topical immunotherapy with diphencyprone (DPCP) for the treatment of severe alopecia areata has been used since 1983 and is felt to be the treatment of choice for chronic extensive alopecia areata. Highly variable results have been reported. The purposes of this study were to evaluate the efficacy of DPCP in the treatment of chronic, extensive alopecia areata and to assess the long-...

The topical immunotherapy is used to treat alopecia areata and recalcitrant warts since the 1970s. Diphencyprone is a contact sensitizer used to treat dermatological conditions resulting from as altered immunological state, such as extensive alopecia areata, being partially effective and safe. Side effects include local eczema with blistering, regional lymphadenopathy and contact urticaria. Rar...

Alopecia areata incognita, also known as diffuse alopecia areata, is a rare form of alopecia areata described predominantly in young women. In cases of alopecia areata incognita, the typical patchy distribution of hair loss in classical alopecia areata is absent, but abrupt and intense hair loss is characteristic. While the clinical picture presented by this disease closely resembles that of te...

Background: Alopecia Areata (AA) is a skin disease which affects 0.2 % of general population. Unlike its little physical impairment, Alopecia areata causes a lot of cosmetic problems but most clinicians do not pay attention to mood disorders and the impaired quality of life as the consequences of disease. Objectives: To evaluate depression and quality of life in Iranian patients with Alopecia a...

Background: Alopecia areata is a common disorder of hair occurring on any hair bearing site of the body and having a great psychosocial impact. Aims: To assess the demographic pattern, clinical aspects, associations and therapeutic response of AA in a tertiary care teaching hospital. Materials & methods: All patients diagnosed with alopecia areata were included in the study. With due consent, t...

Background: Localized and extensive clinical subtypes of alopecia areata (AA) including alopecia totalis and alopecia universalis differ in genetic and immunologic aspects. Objective: Comparison of epidemiologic aspects of localized and extensive subtypes of AA. Patients and Methods: In a prospective descriptive study, 180 patients suffering from AA attending the skin clinics of Razi Hosp...

Alopecia areata is an unpredictable, non-scarring hair loss condition. Patchy alopecia areata sparing gray hairs is rare. Here we present 4 cases with patchy non-scarring hair loss, which attacked pigmented hairs only and spared gray hairs. It should be differentiated from vitiligo, colocalization of vitiligo and alopecia areata, and depigmented hair regrowth after alopecia areata.

Alopecia areata is a common autoimmune skin disease resulting in the loss of hair on the scalp and elsewhere on the body that affects over 146 million people worldwide at some point in their lives. Founded in 1981, the National Alopecia Areata Foundation (NAAF) is a nonprofit organization that supports research to find a cure or acceptable treatment for alopecia areata, supports those with the ...